There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alphatec Holdings (ATEC – Research Report) and Coherus Biosciences (CHRS – Research Report) with bullish sentiments.
Alphatec Holdings (ATEC)
In a report released today, Brooks O’Neil from Lake Street maintained a Buy rating on Alphatec Holdings, with a price target of $20.00. The company’s shares closed last Thursday at $14.00.
According to TipRanks.com, O’Neil is a 3-star analyst with an average return of 3.6% and a 46.8% success rate. O’Neil covers the Healthcare sector, focusing on stocks such as Apollo Medical Holdings, Cardiovascular Systems, and Tandem Diabetes Care.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alphatec Holdings with a $18.00 average price target, representing a 30.8% upside. In a report issued on February 3, Needham also reiterated a Buy rating on the stock with a $18.00 price target.
Coherus Biosciences (CHRS)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Coherus Biosciences today and set a price target of $21.00. The company’s shares closed last Thursday at $7.82.
According to TipRanks.com, Syed is ranked 0 out of 5 stars with an average return of -10.3% and a 43.0% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Unity Biotechnology.
Currently, the analyst consensus on Coherus Biosciences is a Moderate Buy with an average price target of $15.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATEC: